25984 Gastrointestinal adverse events related to study drug and leading to discontinuation through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials

Autor:	Amy Baum-Jones, Melinda Gooderham, Alan M. Mendelsohn, Boni E. Elewski, Stephen J. Rozzo, Jennifer Conner
Rok vydání:	2021
Předmět:	Clinical trial medicine.medical_specialty Study drug business.industry Internal medicine Tildrakizumab medicine Dermatology business Adverse effect Discontinuation
Zdroj:	Journal of the American Academy of Dermatology. 85:AB78
ISSN:	0190-9622
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::96e8cb72309dc3f2489fd1e763d5e390 https://doi.org/10.1016/j.jaad.2021.06.337 Zobrazit plný text záznamu Full Text from ScienceDirect